Ruthenium complexes for galectin inhibition, methods for preparing the same, and their use
Ruthenium complexes with a 3D structure selectively inhibit galectin-1, addressing the lack of effective galectin-1 inhibitors by improving binding interactions and providing therapeutic benefits for cancer and HIV treatment.
JP2026517638APending Publication Date: 2026-06-02ウスタフ ヘミツキーフ プロツェスー アーヴェー チェーエルヴェーヴェーイー +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ウスタフ ヘミツキーフ プロツェスー アーヴェー チェーエルヴェーヴェーイー
- Filing Date
- 2024-03-28
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517638000001_ABST
Abstract
The present invention relates to a compound represented by the general formula (I). 【Chemical 1】 JPEG2026517638000063.jpg39169 (I) In the general formula (I), R 1 , R 2 , R 3 , R 4 , R m are each independently selected from the group consisting of H and (C1 - C6) alkyl; n is 1 or 2; X is CH or N; D, Y, and Z are each independently CH, N, or O; R are each independently H, or acyl or thioacyl; B is selected from the group consisting of a monovalent negatively charged ligand and a neutral ligand; and A is of structure (II) or (III). 【Chemical 2】 JPEG2026517638000064.jpg48169 (II) (III) The present invention further relates to methods for their preparation and their use.
Need to check novelty before this filing date? Find Prior Art